censavudine censavudine censavudine (inn) (bms-986001) is an investigational new drug being developed by bristol myers-squibb for the treatment of hiv infection. it was originally developed at yale university. censavudineclinical dataother names4'-ethynylstavudine, festinavirlegal statuslegal status investigational identifiers iupac name 1--5-methylpyrimidine-2,4-dione cas number634907-30-5pubchem cid3008897chemspider2278330unii6ie83o6ngakeggd10550chemblchembl124363niaid chemdb209894comptox dashboard (epa)dtxsid50212893 echa infocard100.225.812 chemical and physical dataformulac12h12n2o4molar mass248.238 g·mol−13d model (jsmol)interactive image smiles cc1=cn(c(=o)nc1=o)2c=c(o2)(co)c#c inchi inchi=1s/c12h12n2o4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15h,7h2,2h3,(h,13,16,17)/t9-,12+/m1/s1key:osywbjsvkuffsu-skdrfnhksa-n renaming until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with hiv protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).